Related Experiment Video

Updated: May 16, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

PTRF/cavin-1 is essential for multidrug resistance in cancer cells

Jae-Sung Yi1, Dong-Gi Mun, Hyun Lee

  • 1Division of Life Sciences, College of Life Sciences and Biotechnology, Research Institute for Natural Sciences, Korea University, Seoul, 136-701, South Korea, and.

Journal of Proteome Research
|December 11, 2012
PubMed

Insights

Polymerase I and transcript release factor (PTRF) is crucial for multidrug resistance (MDR) in cancer cells. This protein strengthens lipid rafts, enhancing MDR by fortifying these structures.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Cancer Research

Background:

  • Detergent-resistant lipid rafts are implicated in multidrug resistance (MDR) in cancer.
  • Understanding the proteomic composition of lipid rafts is key to elucidating MDR mechanisms.

Purpose of the Study:

  • To investigate the proteomic differences in lipid rafts between sensitive and resistant cancer cells.
  • To identify key proteins involved in MDR within lipid rafts.

Main Methods:

  • Isolation of lipid rafts from MCF-7 and adriamycin-resistant MCF-7/ADR cells.
  • Label-free quantitative proteomics to analyze lipid raft proteomes.
  • PTRF knockdown and assessment of lipid raft quantity and MDR.

Main Results:

  • Polymerase I and transcript release factor (PTRF)/cavin-1 was upregulated in resistant MCF-7/ADR cells.
  • PTRF knockdown reduced lipid raft abundance and decreased MDR in MCF-7/ADR cells.
  • PTRF is associated with P-glycoprotein and caveolin-1 in lipid rafts of resistant cells.

Conclusions:

  • PTRF plays a critical role in establishing and maintaining multidrug resistance in cancer cells.
  • PTRF fortifies lipid rafts, thereby contributing to the MDR phenotype.
  • PTRF is a potential therapeutic target for overcoming MDR in cancer.

More Related Videos

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...